BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143:1422-1429. [PMID: 23715088 DOI: 10.1378/chest.11-2735] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Nishikiori H, Chiba H, Ariki S, Kuronuma K, Otsuka M, Shiratori M, Ikeda K, Watanabe A, Kuroki Y, Takahashi H. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2014;14:196. [PMID: 25488319 DOI: 10.1186/1471-2466-14-196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
2 Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, Golzarri MF, Traslosheros A, Chu SG, Frits ML, Iannaccone CK, Koontz D, Fuhrman C, Weinblatt ME, El-Chemaly SY, Washko GR, Hunninghake GM, Choi AM, Dellaripa PF, Oddis CV, Shadick NA, Ascherman DP, Rosas IO. Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. Am J Respir Crit Care Med 2015;191:1403-12. [PMID: 25822095 DOI: 10.1164/rccm.201411-1950OC] [Cited by in Crossref: 75] [Cited by in F6Publishing: 45] [Article Influence: 10.7] [Reference Citation Analysis]
3 Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche. Eur Respir Rev 2018;27:170117. [DOI: 10.1183/16000617.0117-2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
4 Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep 2020;10:15620. [PMID: 32973215 DOI: 10.1038/s41598-020-72607-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Johannson KA, Ley B, Collard HR. Models of disease behavior in idiopathic pulmonary fibrosis. BMC Med 2015;13:165. [PMID: 26400574 DOI: 10.1186/s12916-015-0403-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saito S, Lasky JA, Hagiwara K, Kondoh Y. Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective. Respir Investig 2018;56:375-83. [PMID: 30061050 DOI: 10.1016/j.resinv.2018.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7083. [PMID: 28591049 DOI: 10.1097/MD.0000000000007083] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Ley B. COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? No. Chest 2019;156:205-8. [PMID: 31395256 DOI: 10.1016/j.chest.2019.03.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Jiang Y, Luo Q, Han Q, Huang J, Ou Y, Chen M, Wen Y, Mosha SS, Deng K, Chen R. Sequential changes of serum KL-6 predict the progression of interstitial lung disease. J Thorac Dis 2018;10:4705-14. [PMID: 30233842 DOI: 10.21037/jtd.2018.07.76] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
10 Dellaripa PF. Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clin Immunol 2018;186:71-3. [PMID: 28923440 DOI: 10.1016/j.clim.2017.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
11 Ali MF, Dasari H, Van Keulen VP, Cornec D, Vasmatzis G, Peikert T, Carmona EM. Microbial Antigens Stimulate Metalloprotease-7 Secretion in Human B-Lymphocytes Using mTOR-Dependent and Independent Pathways. Sci Rep 2017;7:3869. [PMID: 28634370 DOI: 10.1038/s41598-017-04199-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Krafft E, Laurila HP, Peters IR, Bureau F, Peeters D, Day MJ, Rajamäki MM, Clercx C. Analysis of gene expression in canine idiopathic pulmonary fibrosis. Vet J 2013;198:479-86. [PMID: 24120450 DOI: 10.1016/j.tvjl.2013.08.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K, Nakatsuka Y, Tokuda S, Oga T, Hirai T, Nagai S, Chin K, Mishima M. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00019-2016. [PMID: 28875146 DOI: 10.1183/23120541.00019-2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
14 Wang J, Zheng P, Huang Z, Huang H, Xue M, Liao C, Sun B, Zhong N. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulm Med 2020;20:315. [PMID: 33267857 DOI: 10.1186/s12890-020-01336-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Tzouvelekis A, Herazo-Maya JD, Slade M, Chu JH, Deiuliis G, Ryu C, Li Q, Sakamoto K, Ibarra G, Pan H, Gulati M, Antin-Ozerkis D, Herzog EL, Kaminski N. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology 2017;22:486-93. [PMID: 27761978 DOI: 10.1111/resp.12920] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
16 Juge PA, Crestani B, Dieudé P. Recent advances in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Pulm Med 2020;26:477-86. [PMID: 32701675 DOI: 10.1097/MCP.0000000000000710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wang W, Wang Q, Zou Z, Zheng F, Zhang A. Human arsenic exposure and lung function impairment in coal-burning areas in Guizhou, China. Ecotoxicology and Environmental Safety 2020;190:110174. [DOI: 10.1016/j.ecoenv.2020.110174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
18 Cabrera Cesar E, Lopez-Lopez L, Lara E, Hidalgo-San Juan MV, Parrado Romero C, Palencia JLRS, Martín-Montañez E, Garcia-Fernandez M. Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease. J Clin Med 2021;10:3167. [PMID: 34300333 DOI: 10.3390/jcm10143167] [Reference Citation Analysis]
19 Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol 2018;68-69:404-21. [PMID: 29408012 DOI: 10.1016/j.matbio.2018.01.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
20 Bowman WS, Echt GA, Oldham JM. Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. Front Med (Lausanne) 2021;8:680997. [PMID: 34041256 DOI: 10.3389/fmed.2021.680997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Morais A, Beltrão M, Sokhatska O, Costa D, Melo N, Mota P, Marques A, Delgado L. Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir Med 2015;109:1063-8. [PMID: 26174192 DOI: 10.1016/j.rmed.2015.06.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
22 Matsuzawa Y, Kawashima T, Kuwabara R, Hayakawa S, Irie T, Yoshida T, Rikitake H, Wakabayashi T, Okada N, Kawashima K, Suzuki Y, Shirai K. Change in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 2015;32:1-6. [PMID: 25862941 DOI: 10.1016/j.pupt.2015.03.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
23 Gille T, Didier M, Boubaya M, Moya L, Sutton A, Carton Z, Baran-marszak F, Sadoun-danino D, Israël-biet D, Cottin V, Gagnadoux F, Crestani B, d'Ortho M, Brillet P, Valeyre D, Nunes H, Planès C; collaborators. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis. Eur Respir J 2017;49:1601934. [DOI: 10.1183/13993003.01934-2016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
24 Verleden SE, Braubach P, Kuehnel M, Dickgreber N, Brouwer E, Tittmann P, Laenger F, Jonigk D. Molecular approach to the classification of chronic fibrosing lung disease-there and back again. Virchows Arch 2021;478:89-99. [PMID: 33169196 DOI: 10.1007/s00428-020-02964-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Hambly N, Shimbori C, Kolb M. Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology. 2015;20:1010-1022. [PMID: 26109466 DOI: 10.1111/resp.12569] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
26 Brownell R, Kaminski N, Woodruff PG, Bradford WZ, Richeldi L, Martinez FJ, Collard HR. Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016;193:1213-8. [PMID: 26991475 DOI: 10.1164/rccm.201601-0169CI] [Cited by in Crossref: 48] [Cited by in F6Publishing: 16] [Article Influence: 9.6] [Reference Citation Analysis]
27 Zheng P, Zheng X, Takehiro H, Cheng ZJ, Wang J, Xue M, Lin Q, Huang Z, Huang H, Liao C, Sun B. The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease. J Transl Int Med 2021;9:212-22. [PMID: 34900632 DOI: 10.2478/jtim-2021-0040] [Reference Citation Analysis]
28 Stainer A, Faverio P, Busnelli S, Catalano M, Della Zoppa M, Marruchella A, Pesci A, Luppi F. Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions. Int J Mol Sci 2021;22:6255. [PMID: 34200784 DOI: 10.3390/ijms22126255] [Reference Citation Analysis]
29 Magnini D, Montemurro G, Iovene B, Tagliaboschi L, Gerardi RE, Lo Greco E, Bruni T, Fabbrizzi A, Lombardi F, Richeldi L. Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration 2017;93:379-95. [DOI: 10.1159/000475780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
30 Axelsson GT, Gudmundsson G. Interstitial lung abnormalities - current knowledge and future directions. Eur Clin Respir J 2021;8:1994178. [PMID: 34745461 DOI: 10.1080/20018525.2021.1994178] [Reference Citation Analysis]
31 Nomden M, Beljaars L, Verkade HJ, Hulscher JBF, Olinga P. Current Concepts of Biliary Atresia and Matrix Metalloproteinase-7: A Review of Literature. Front Med (Lausanne) 2020;7:617261. [PMID: 33409288 DOI: 10.3389/fmed.2020.617261] [Reference Citation Analysis]
32 Campo I, Zorzetto M, Bonella F. Facts and promises on lung biomarkers in interstitial lung diseases. Expert Review of Respiratory Medicine 2015;9:437-57. [DOI: 10.1586/17476348.2015.1062367] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
33 Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med 2014;2:4. [PMID: 25505696 DOI: 10.1186/2213-0802-2-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
34 Sokai A, Handa T, Tanizawa K, Oga T, Uno K, Tsuruyama T, Kubo T, Ikezoe K, Nakatsuka Y, Tanimura K, Muro S, Hirai T, Nagai S, Chin K, Mishima M. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res 2015;16:120. [PMID: 26415518 DOI: 10.1186/s12931-015-0280-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
35 Imai-Matsushima A, Martin-Sancho L, Karlas A, Imai S, Zoranovic T, Hocke AC, Mollenkopf HJ, Berger H, Meyer TF. Long-Term Culture of Distal Airway Epithelial Cells Allows Differentiation Towards Alveolar Epithelial Cells Suited for Influenza Virus Studies. EBioMedicine 2018;33:230-41. [PMID: 29937069 DOI: 10.1016/j.ebiom.2018.05.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
36 Isshiki T, Matsuyama H, Yamaguchi T, Morita T, Ono J, Nunomura S, Izuhara K, Sakamoto S, Homma S, Kishi K. Plasma matrix metalloproteinase 7, CC-chemokine ligand 18, and periostin as markers for pulmonary sarcoidosis. Respiratory Investigation 2020;58:479-87. [DOI: 10.1016/j.resinv.2020.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Yang M, Li Y, Meng T, Zhang L, Niu Y, Dai Y, Gao W, Bloom MS, Dong G, Zheng Y. Ultrafine CB-induced small airway obstruction in CB-exposed workers and mice. Science of The Total Environment 2019;671:866-73. [DOI: 10.1016/j.scitotenv.2019.03.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Ikeda K, Chiba H, Nishikiori H, Azuma A, Kondoh Y, Ogura T, Taguchi Y, Ebina M, Sakaguchi H, Miyazawa S, Suga M, Sugiyama Y, Nukiwa T, Kudoh S, Takahashi H; Pirfenidone Clinical Study Group in Japan. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res 2020;21:316. [PMID: 33256760 DOI: 10.1186/s12931-020-01582-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Wilson AM, Clark AB, Cahn A, Chilvers ER, Fraser W, Hammond M, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M. Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. Efficacy Mech Eval 2021;8:1-110. [DOI: 10.3310/eme08090] [Reference Citation Analysis]
40 Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res 2016;5:F1000 Faculty Rev-1046. [PMID: 27303645 DOI: 10.12688/f1000research.8209.1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
41 Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Rev Respir Med 2022. [PMID: 35695895 DOI: 10.1080/17476348.2022.2089116] [Reference Citation Analysis]
42 Zhang T, Shen P, Duan C, Gao L. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:745233. [PMID: 34956179 DOI: 10.3389/fimmu.2021.745233] [Reference Citation Analysis]
43 Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest 2020;158:646-59. [PMID: 32268131 DOI: 10.1016/j.chest.2020.03.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
44 Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J Clin Med 2018;7:E201. [PMID: 30082599 DOI: 10.3390/jcm7080201] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 19.8] [Reference Citation Analysis]
45 Huang TH, Kuo CW, Chen CW, Tseng YL, Wu CL, Lin SH. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulm Med 2021;21:165. [PMID: 33992083 DOI: 10.1186/s12890-021-01530-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Nathan N, Corvol H, Amselem S, Clement A. Biomarkers in Interstitial lung diseases. Paediatric Respiratory Reviews 2015;16:219-24. [DOI: 10.1016/j.prrv.2015.05.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
47 Nair GB, Matela A, Kurbanov D, Raghu G. Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. Expert Rev Respir Med 2016;10:699-711. [PMID: 27094006 DOI: 10.1080/17476348.2016.1177461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
48 Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, Degryse AL, Mitchell DB, Polosukhin VV, Rickman OB, Choi L, Cheng DS, McConaha ME, Jones BR, Gleaves LA, McMahon FB, Worrell JA, Solus JF, Ware LB, Lee JW, Massion PP, Zaynagetdinov R, White ES, Kurtis JD, Johnson JE, Groshong SD, Lancaster LH, Young LR, Steele MP, Phillips Iii JA, Cogan JD, Loyd JE, Lawson WE, Blackwell TS. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 2015;191:417-26. [PMID: 25389906 DOI: 10.1164/rccm.201406-1162OC] [Cited by in Crossref: 99] [Cited by in F6Publishing: 58] [Article Influence: 14.1] [Reference Citation Analysis]
49 Norman KC, O'Dwyer DN, Salisbury ML, DiLillo KM, Lama VN, Xia M, Gurczynski SJ, White ES, Flaherty KR, Martinez FJ, Murray S, Moore BB, Arnold KB. Identification of a unique temporal signature in blood and BAL associated with IPF progression. Sci Rep 2020;10:12049. [PMID: 32694604 DOI: 10.1038/s41598-020-67956-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Niu R, Liu Y, Zhang Y, Zhang Y, Wang H, Wang Y, Wang W, Li X. iTRAQ-Based Proteomics Reveals Novel Biomarkers for Idiopathic Pulmonary Fibrosis. PLoS One 2017;12:e0170741. [PMID: 28122020 DOI: 10.1371/journal.pone.0170741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
51 Ohkubo H, Taniguchi H, Kondoh Y, Yagi M, Furukawa T, Johkoh T, Arakawa H, Fukuoka J, Niimi A. A Volumetric Computed Tomography Analysis of the Normal Lung in Idiopathic Pulmonary Fibrosis: The Relationship with the Survival. Intern Med 2018;57:929-37. [PMID: 29269656 DOI: 10.2169/internalmedicine.9508-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
52 Hammond M, Clark AB, Cahn AP, Chilvers ER, Fraser WD, Livermore DM, Maher TM, Parfrey H, Swart AM, Stirling S, Thickett D, Whyte M, Wilson A. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials 2018;19:89. [PMID: 29402332 DOI: 10.1186/s13063-018-2453-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
53 Chiba H, Otsuka M, Takahashi H. Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review. Respiratory Investigation 2018;56:384-91. [DOI: 10.1016/j.resinv.2018.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
54 Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Semin Arthritis Rheum 2020;50:480-91. [PMID: 32089354 DOI: 10.1016/j.semarthrit.2020.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
55 Aloisio E, Braga F, Puricelli C, Panteghini M. Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Chem Lab Med 2021;59:1400-8. [PMID: 33831978 DOI: 10.1515/cclm-2021-0199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Xue C, Wu N, Li X, Qiu M, Du X, Ye Q. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study. BMC Pulm Med. 2017;17:144. [PMID: 29149883 DOI: 10.1186/s12890-017-0489-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
57 Kim HC, Ji W, Kim MY, Colby TV, Jang SJ, Lee CK, Han SB, Kim DS. Interstitial pneumonia related to undifferentiated connective tissue disease: pathologic pattern and prognosis. Chest 2015;147:165-72. [PMID: 25211168 DOI: 10.1378/chest.14-0272] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
58 Ohkubo H, Nakagawa H, Niimi A. Computer-based quantitative computed tomography image analysis in idiopathic pulmonary fibrosis: A mini review. Respiratory Investigation 2018;56:5-13. [DOI: 10.1016/j.resinv.2017.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
59 Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis. Dis Markers 2016;2016:4759040. [PMID: 27293304 DOI: 10.1155/2016/4759040] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 8.5] [Reference Citation Analysis]
60 Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med 2015;21:470-8. [PMID: 26132817 DOI: 10.1097/MCP.0000000000000187] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
61 Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, Sarma N, Ma SF, Haczku A, Sperling A, Strek ME, Noth I, Oldham JM. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest 2020;158:1526-34. [PMID: 32450241 DOI: 10.1016/j.chest.2020.04.066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
62 Gobert GN, Burke ML, McManus DP, Ellis MK, Chuah C, Ramm GA, Wang Y, Li Y. Transcriptional profiling of chronic clinical hepatic schistosomiasis japonica indicates reduced metabolism and immune responses. Parasitology 2015;142:1453-68. [PMID: 26216487 DOI: 10.1017/S0031182015000682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
63 Puxeddu E, Rogliani P. Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis. World J Respirol 2016; 6(1): 14-23 [DOI: 10.5320/wjr.v6.i1.14] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Piper AJ, Wort SJ, Renzoni EA, Kouranos V. Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep. Respirology 2018;23:421-33. [PMID: 29471594 DOI: 10.1111/resp.13273] [Reference Citation Analysis]
65 Nakano A, Ohkubo H, Taniguchi H, Kondoh Y, Matsuda T, Yagi M, Furukawa T, Kanemitsu Y, Niimi A. Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Sci Rep 2020;10:2312. [PMID: 32047177 DOI: 10.1038/s41598-020-59100-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
66 Goodwin AT, Jenkins G. Molecular Endotyping of Pulmonary Fibrosis. Chest 2016;149:228-37. [DOI: 10.1378/chest.15-1511] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
67 Chung C, Kim J, Cho HS, Kim HC. Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis. Sci Rep 2022;12:8564. [PMID: 35595812 DOI: 10.1038/s41598-022-12399-8] [Reference Citation Analysis]
68 Meng K, Tian M, Gui X, Xie M, Gao Y, Shi S, Zhao T, Xiao Y, Cai H, Ding J. Human epididymis protein 4 is associated with severity and poor prognosis of connective tissue disease-associated interstitial lung disease with usual interstitial pneumonia pattern. International Immunopharmacology 2022;108:108704. [DOI: 10.1016/j.intimp.2022.108704] [Reference Citation Analysis]
69 Inchingolo R, Varone F, Sgalla G, Richeldi L. Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 2018;13:39-51. [DOI: 10.1080/17476348.2019.1553620] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
70 Tatler AL. Recent advances in the non-invasive assessment of fibrosis using biomarkers. Curr Opin Pharmacol 2019;49:110-5. [PMID: 31756570 DOI: 10.1016/j.coph.2019.09.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Zhang J, Wang Y, Zhang S, Li J, Fang H. Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients. Exp Ther Med 2020;19:2195-201. [PMID: 32104284 DOI: 10.3892/etm.2020.8431] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 Tomos IP, Tzouvelekis A, Aidinis V, Manali ED, Bouros E, Bouros D, Papiris SA. Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the 'bed' that counts and not 'the sleepers'. Expert Rev Respir Med 2017;11:299-309. [PMID: 28274188 DOI: 10.1080/17476348.2017.1300533] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
73 Armstrong HF, Podolanczuk AJ, Barr RG, Oelsner EC, Kawut SM, Hoffman EA, Tracy R, Kaminski N, McClelland RL, Lederer DJ. Serum Matrix Metalloproteinase-7, Respiratory Symptoms, and Mortality in Community-Dwelling Adults. MESA (Multi-Ethnic Study of Atherosclerosis). Am J Respir Crit Care Med 2017;196:1311-7. [PMID: 28570100 DOI: 10.1164/rccm.201701-0254OC] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
74 Doyle TJ, Dellaripa PF, Rosas IO. Risk Factors and Biomarkers of RA-ILD. In: Fischer A, Lee JS, editors. Lung Disease in Rheumatoid Arthritis. Cham: Springer International Publishing; 2018. pp. 59-72. [DOI: 10.1007/978-3-319-68888-6_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
75 Kim HC, Choi KH, Jacob J, Song JW. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. PLoS One 2020;15:e0229997. [PMID: 32163457 DOI: 10.1371/journal.pone.0229997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
76 De Lauretis A, Renzoni EA. Molecular Biomarkers in Interstitial Lung Diseases. Mol Diagn Ther 2014;18:505-22. [DOI: 10.1007/s40291-014-0109-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
77 Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014;307:L681-91. [PMID: 25260757 DOI: 10.1152/ajplung.00014.2014] [Cited by in Crossref: 113] [Cited by in F6Publishing: 94] [Article Influence: 14.1] [Reference Citation Analysis]
78 Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2015;11:359-70. [PMID: 25767391 DOI: 10.2147/TCRM.S69716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
79 Westermann-clark E, Soundararajan R, Fukumoto J, Patil SS, Stearns TM, Saji S, Czachor A, Hernandez-cuervo H, Breitzig M, Krishnamurthy S, Lockey RF, Kolliputi N. Matrix Metalloproteinase 7 Expression and Apical Epithelial Defects in Atp8b1 Mutant Mouse Model of Pulmonary Fibrosis. Biomolecules 2022;12:283. [DOI: 10.3390/biom12020283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Jee AS, Sahhar J, Youssef P, Bleasel J, Adelstein S, Nguyen M, Corte TJ. Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease – frontiers and horizons. Pharmacology & Therapeutics 2019;202:40-52. [DOI: 10.1016/j.pharmthera.2019.05.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
81 Ali MF, Egan AM, Shaughnessy GF, Anderson DK, Kottom TJ, Dasari H, Van Keulen VP, Aubry MC, Yi ES, Limper AH, Peikert T, Carmona EM. Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol 2021;64:722-33. [PMID: 33689587 DOI: 10.1165/rcmb.2020-0387OC] [Reference Citation Analysis]